Literature DB >> 15607116

Metabolic alteration of the N-glycan structure of a protein from patients with a heterozygous protein deficiency.

Fuming Zhang1, Andrew D Bries, Sybil C Lang, Qun Wang, David W Murhammer, John M Weiler, Robert J Linhardt.   

Abstract

Glycosylation, an important post-translation modification, could alter biological activity or influence the clearance rates of glycoproteins. We report here the first example of a heterozygous protein deficiency leading to metabolic alteration of N-glycan structures in residual secreted protein. Analysis of C1 esterase inhibitor (C1INH) glycans from normal individuals and patients with hereditary deficiency of C1INH demonstrated identical O-glycan structures but the N-glycans of patients with a heterozygous genetic deficiency were small, highly charged and lacked sialidase releasable N-acetylneuraminic acid. Structural studies indicate that the charge character of these aberrant N-glycan structures may result from the presence of mannose-6-phosphate residues. These residues might facilitate secretion of C1INH through an alternate lysosomal pathway, possibly serving as a compensatory mechanism to enhance plasma levels of C1INH in these deficient patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15607116      PMCID: PMC4137563          DOI: 10.1016/j.bbadis.2004.08.006

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  26 in total

Review 1.  The biogenesis of lysosomes.

Authors:  S Kornfeld; I Mellman
Journal:  Annu Rev Cell Biol       Date:  1989

2.  Semiautomated procedures for evaluation of carbohydrate-deficient transferrin in the diagnosis of alcohol abuse.

Authors:  P Bean; K Liegmann; T Løvli; C Westby; E Sundrehagen
Journal:  Clin Chem       Date:  1997-06       Impact factor: 8.327

3.  Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate.

Authors:  A T Waytes; F S Rosen; M M Frank
Journal:  N Engl J Med       Date:  1996-06-20       Impact factor: 91.245

4.  Interaction of 125I-labelled complement subcomponents C-1r and C-1s with protease inhibitors in plasma.

Authors:  R B Sim; A Reboul; G J Arlaud; C L Villiers; M G Colomb
Journal:  FEBS Lett       Date:  1979-01-01       Impact factor: 4.124

5.  Size and shape of human C1-inhibitor.

Authors:  E Odermatt; H Berger; Y Sano
Journal:  FEBS Lett       Date:  1981-08-31       Impact factor: 4.124

6.  Activation of the early components of the classical complement pathway under physiologic conditions.

Authors:  R J Ziccardi
Journal:  J Immunol       Date:  1981-05       Impact factor: 5.422

7.  Proteolysis and deglycosylation of human C1 inhibitor. Effect on functional properties.

Authors:  A Reboul; M H Prandini; M G Colomb
Journal:  Biochem J       Date:  1987-05-15       Impact factor: 3.857

8.  Two-domain structure of the native and reactive centre cleaved forms of C1 inhibitor of human complement by neutron scattering.

Authors:  S J Perkins; K F Smith; S Amatayakul; D Ashford; T W Rademacher; R A Dwek; P J Lachmann; R A Harrison
Journal:  J Mol Biol       Date:  1990-08-05       Impact factor: 5.469

9.  Expression of C1 esterase inhibitor by the baculovirus expression vector system: preparation, purification, and characterization.

Authors:  M W Wolff; F Zhang; J J Roberg; E E Caldwell; P R Kaul; J N Serrahn; D W Murhammer; R J Linhardt; J M Weiler
Journal:  Protein Expr Purif       Date:  2001-08       Impact factor: 1.650

10.  Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization.

Authors:  S C Bock; K Skriver; E Nielsen; H C Thøgersen; B Wiman; V H Donaldson; R L Eddy; J Marrinan; E Radziejewska; R Huber
Journal:  Biochemistry       Date:  1986-07-29       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.